Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PER2 | O15055 | 4/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239649 | 1.00 | GRM2 (0.35) | GRM2NR1H3KCNH2MAOBPER2 | |
| SCHEMBL257413 | 0.80 | MAOB (0.41) | KCNH2MAOBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7248052 | 0.78 | NR1H3 (0.40) | GRM2NR1H3KCNH2MAOBPER2 | |
| SCHEMBL7526000 | 0.78 | NR1H3 (0.40) | GRM2NR1H3KCNH2MAOBPER2 | |
| SCHEMBL7244459 | 0.78 | NR1H3 (0.40) | GRM2NR1H3KCNH2MAOBPER2 | |
| SCHEMBL1120896 | 0.78 | GAA (0.42) | NR1H3MAOBALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL5194303 | 0.78 | NR1H3 (0.38) | GRM2NR1H3MAOB | |
| SCHEMBL5193993 | 0.75 | NR1H3 (0.37) | GRM2NR1H3KCNH2MAOB | |
| SCHEMBL1120784 | 0.75 | NPSR1 (0.39) | NR1H3MAOBALDH1A1CYP2D6MAPT | |
| SCHEMBL7244999 | 0.73 | GRM2 (0.47) | GRM2PER2CRY1CRY2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | GRM2 1395/4885NR1H3 76/4885KCNH2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.